What Emocog does

Emocog is a South Korea-based digital therapeutics company founded in 2021 that develops software-based cognitive interventions for patients with mild cognitive impairment (MCI) and dementia risk, serving healthcare providers, hospital systems, and pharmaceutical partners across Korea, Germany, and preparation-stage U.S. operations. The company's flagship product Cogthera is a clinically validated digital therapeutic that continuously monitors patients' cognitive functions and delivers personalized cognitive training through a voice-based conversational interface with adaptive difficulty adjustment based on patient performance. Cogthera was designated as Korea's 35th Innovative Medical Device by the MFDS — the first cognitive intervention treatment software for MCI approved in the country — and is simultaneously pursuing Germany's DiGA fast-track reimbursement pathway through subsidiary Cogthera GmbH, with U.S. FDA pre-submission completed.

The company's product portfolio spans the full dementia care continuum: MemoryPick (기억콕콕) for mobile cognitive screening, Cogthera KR/DE for MCI treatment, PDT for Parkinson's disease diagnostic assistance, AlzVoice for voice-based memory and attention assessment, and Spectracheck (an IVD reagent). Through the 2023 acquisition of Happymind, Emocog extended into pediatric and adolescent learning disorder solutions including the CAT (Comprehensive Attention Test), CLT (Comprehensive Learning Test), NeuLearn English vocabulary app, and dyscalculia treatment programs. The 2024 acquisition of PL Group added CNS specialty drug distribution capability, creating vertical integration potential between pharmaceutical sales and digital therapeutic prescriptions. Strategic grand partnerships with Korea Eisai, Quanterix, Naver Cloud, NHN Waplat, and SK Telecom position the company within an integrated diagnostic-therapeutic-cloud ecosystem.

Emocog operates a B2B enterprise model with revenue generated primarily through healthcare provider prescriptions and institutional deployments of its regulated medical device products. The company sells through hospital channels (validated across 7 Korean university hospitals including Inje University Ilsan Paik Hospital, Ajou University Hospital, and Seoul National University Hospital), pursues regulatory-approved reimbursement pathways in Korea (MFDS) and Germany (DiGA), and leverages clinical conferences (CES, IFA, MEDICA, AD/PD) for market visibility. The company has raised approximately $27.2M across three funding rounds from Korean institutional investors including Naver, Kakao, Stonebridge Ventures, KB Investment, IBK, Shinhan Venture Investment, and Green Cross Holdings, and holds 23 related patents (9 registered, 14 filed) with 5 SCI-indexed publications backing its clinical claims.

Name

Emocog

Legal name

Emocog Inc.

Website

https://emocog.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Emocog is a South Korea-based digital therapeutics company that develops and commercializes Cogthera, an MFDS-approved software for cognitive training in patients with mild cognitive impairment, serving hospitals, healthcare providers, and pharmaceutical partners across Korea and Germany.

Ownership category

akta.pro rank

Product category

Digital Therapeutics (Cognitive Healthcare Software)

NAICS

Services for the Elderly and Persons with Disabilities (62412), Nursing and Residential Care Facilities (623)

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Dementia/Alzheimer’s Care Management & Behavioral Support (HLADALAF), Memory Care Care Management & Navigation (Dementia Care Coordination) (HLADACAJ), Prescription Digital Therapeutics (PDT) (HLACANAB)

Keywords

• Digital therapeutics
• Cognitive training software
• Dementia screening tools
• Mild cognitive impairment treatment
• Brain health platforms

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Cogthera Digital Therapeutics (Korea): Cogthera generates revenue as a regulated medical device prescribed by healthcare professionals. Approved by MFDS (Korea FDA) as the 35th Innovative Medical Device for mild cognitive impairment treatment.
2. Cogthera DE (Germany DiGA): Digital therapeutic pursuing German DiGA (Digital treatments and medical applications) fast-track pathway through BfArM, enabling fast market entry with high insurance reimbursement rates.
3. Cognitive Assessment Services: MemoryPick and other cognitive assessment tools provided as screening services for dementia risk detection.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Emocog develops and markets digital therapeutics (DTx) for cognitive impairment and dementia care, anchored by Cogthera — a smartphone-based cognitive training software for patients aged 55-85 with mild cognitive impairment (MCI). The portfolio extends to mobile cognitive assessment (MemoryPick), voice-based verbal evaluation (AlzVoice), Parkinson's diagnostic support (PDT), and learning disability solutions (CAT, CLT, NeuLearn) acquired through Happymind. Products are deployed under healthcare professional supervision in Korea and pursued via Germany's DiGA fast-track pathway for reimbursement.

Product overview

Emocog is a digital healthcare platform that develops and offers products across two main categories: dementia solutions and learning disorder solutions. The dementia ecosystem includes MemoryPick (mobile cognitive assessment), Cogthera KR/DE (digital therapeutics for MCI), PDT (Parkinson's diagnostic assistant), and AlzVoice (voice-based cognitive assessment). Following the acquisition of Happymind, Emocog expanded into learning disorder solutions including CAT (attention testing), CLT (learning disability screening), NeuLearn (English vocabulary learning), and a dyscalculia treatment program. The company operates a B2B model targeting healthcare providers, pharmaceutical partners, and educational institutions.

Differentiator

Problem solved

Functional benefit

Brands

• Cogthera: Digital therapeutic device for mild cognitive impairment (MCI) providing personalized cognitive training. Available as Cogthera KR (Korea) and Cogthera DE (Germany/DiGA version). Government-approved and designated as 35th Innovative Medical Device in Korea.
• MemoryPick (기억콕콕)
• PDT
• AlzVoice
• CAT (Comprehensive Attention Test)
• CLT (Comprehensive Learning Test)
• NeuLearn
• sCAT
• Spectracheck

Quantifiable outcome

• Delays cognitive decline progression in MCI patients
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, major and supporting.

• QuanterixcoreStrategic or Co-development Partner · 23 March 2026Collaboration at AD/PD 2026 conference to enhance diagnostic capabilities in U.S. and Korean markets, leveraging blood-based biomarkers and digital therapeutics to improve patient access to diagnosis and treatment while monitoring disease progression.
• Korea Eisai (Eisai Korea)coreStrategic or Co-development Partner · 7 December 2025Korea Eisai, subsidiary of Japanese pharmaceutical company Eisai, partnered with Emocog as part of open innovation strategy in digital healthcare focused on dementia prevention, diagnosis, and management. Emocog is one of the startups collaborating with Eisai Korea, which also participated in government-led public-private partnership programs.
• Naver CloudmajorStrategic or Co-development PartnerSigned MOU with Naver Cloud for cloud infrastructure and technology partnership.
• NHN WaplatmajorStrategic or Co-development PartnerSigned business agreement with NHN Waplat for technology collaboration and platform integration.
• HappymindcoreStrategic or Co-development PartnerHappymind is a learning disability solution company with high domestic market share for CAT (Comprehensive Attention Test). Emocog acquired Happymind to share development technology, know-how, and networks for rapid growth and business expansion.
• Share & ServicesupportingStrategic or Co-development PartnerAcquired Share & Service, a company developing respiratory rehabilitation digital therapeutics.
• PL GroupsupportingStrategic or Co-development PartnerAcquired PL Group, a CNS specialty drug distribution and sales company.
• Grand Partnership: Brightonix, Korea Eisai, DuchemBio, Neurophet, LabGenomics, PeopleBio, GCcarecoreStrategic or Co-development PartnerStrategic grand partnerships formed for comprehensive digital healthcare ecosystem development in dementia care, combining diagnostics, therapeutics, and healthcare services.
• 5-HT Digital HubsupportingGTM or Marketing PartnerGerman startup ecosystem hub where Cogthera GmbH is located; awarded Healthcare for Pharma prize.
• SK TelecomsupportingTechnology or IntegrationTechnology partnership with Korean telecom provider for digital health solutions.
• Digital Therapeutics Alliance (DTA)supportingOthersMembership in the Digital Therapeutics Alliance for industry standards and best practices.

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Selfapy: Berlin-based DiGA-approved digital therapeutics company for mental health indications. Directly comparable DTx model targeting German reimbursement, providing a benchmark for regulatory and commercial execution.
• Memodio: German digital therapeutic for mild cognitive impairment, DiGA-listed and reimbursed. Closest direct competitor to Cogthera DE, competing for the same German payer channel and MCI patient population.
• neotiv: German digital health company offering a cognitive health app for memory monitoring and MCI support, often positioned alongside DiGA products. Direct competitor for patients and clinical partners in Germany.
• Cognivue: US-based FDA-cleared digital cognitive assessment device for early detection of MCI and dementia. Comparable to Emocog's MemoryPick / AlzVoice on the screening side, with established US distribution.
• Altoida: US-based digital cognitive assessment platform with FDA Breakthrough Device designation for predicting MCI conversion to Alzheimer's. Competes with Emocog on digital biomarkers and early dementia detection.
• Posit Science (BrainHQ): US digital cognitive training company with extensive clinical evidence and major payer partnerships (Medicare). Closest comparator to Cogthera on the cognitive training side, with deeper US commercial footprint.
• NeuroNation: German consumer and clinical cognitive training app with millions of users, scientifically validated exercises. Adjacent competitor in the same cognitive-training category, though positioned more as a wellness product than a prescribed DTx.
• GAIA AG: German pioneer in DiGA-approved digital therapeutics with multiple listed products. Closely comparable business model for regulatory navigation, payer contracting, and evidence generation in the German market.
• Neurotrack Technologies: US digital health company offering cognitive assessment tools for dementia risk screening. Direct competitor to MemoryPick on the screening side, with established enterprise health partnerships.

Broad incumbents

• MindMaze: Swiss-based neurotechnology company building digital therapeutics and assessment tools for neurological conditions including stroke, MCI, and Parkinson's. Broader portfolio than Emocog but overlaps in cognitive assessment and DTx for neurodegeneration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emocog